Atilio Reyes Romero

Dr. Atilio Reyes Romero

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2019 in Science Advances
Verified
Journal Article
Open access
PDF file
CNConstantinos G. Neochoritis
Constantinos G. Neochoritis
SSShabnam Shaabani
Shabnam Shaabani
MAMaryam Ahmadianmoghaddam
Maryam Ahmadianmoghaddam
TZTryfon Zarganes-Tzitzikas
Tryfon Zarganes-Tzitzikas
LGLi Gao
Li Gao
ADAlexander Dömling
Alexander Dömling
Nanoliter acoustic dispensing technology is an efficient way to synthesize large, diverse, and complex libraries of boronic acids.

17 January 2023 in Green Chemistry
Verified
Journal Article
Open access
PDF file
LGLi Gao
Li Gao
SSShabnam Shaabani
Shabnam Shaabani
ARAtilio Reyes Romero
Atilio Reyes Romero
RXRuixue Xu
Ruixue Xu
MAMaryam Ahmadianmoghaddam
Maryam Ahmadianmoghaddam
ADAlexander Dömling
Alexander Dömling
Sustainable synthesis of highly diverse screening libraries of small molecules.

26 March 2021 in Molecules
Verified
Journal Article
Open access
PDF file
ARAngel J. Ruiz-Moreno
Angel J. Ruiz-Moreno
ARAtilio Reyes Romero
Atilio Reyes Romero
ADAlexander Dömling
Alexander Dömling
Marco Velasco-VelazquezMarco Velasco-Velazquez
Marco Velasco-Velazquez
CD44 promotes metastasis, chemoresistance, and stemness in different types of cancer and is a target for the development of new anti-cancer therapies. All CD44 isoforms share a common N-terminal domain that binds to hyaluronic acid (HA). Herein, we used a computational approach to design new potential CD44 antagonists and evaluate their target-binding ability. By analyzing 30 crystal structures of the HA-binding domain (CD44HAbd), we characterized a subdomain that binds to 1,2,3,4-tetrahydroisoquinoline (THQ)-containing compounds and is adjacent to residues essential for HA interaction. By computational combinatorial chemistry (CCC), we designed 168,190 molecules and compared their conformers to a pharmacophore containing the key features of the crystallographic THQ binding mode. Approximately 0.01% of the compounds matched the pharmacophore and were analyzed by computational docking and molecular dynamics (MD). We identified two compounds, Can125 and Can159, that bound to human CD44HAbd (hCD44HAbd) in explicit-solvent MD simulations and therefore may elicit CD44 blockage. These compounds can be easily synthesized by multicomponent reactions for activity testing and their binding mode, reported here, could be helpful in the design of more potent CD44 antagonists.


28 November 2022 in Molecules
Verified
Journal Article
Open access
PDF file
ARAtilio Reyes Romero
Atilio Reyes Romero
KKKatarzyna Kubica
Katarzyna Kubica
RKRadoslaw Kitel
Radoslaw Kitel
IRIsmael Alejandro Rodriguez
Ismael Alejandro Rodriguez
KMKatarzyna Magiera-Mularz
Katarzyna Magiera-Mularz
ESEwa Surmiak
Ewa Surmiak
By binding to the spliceosomal protein Snu66, the human ubiquitin-like protein Hub1 is a modulator of the spliceosome performance and facilitates alternative splicing. Small molecules that bind to Hub1 would be of interest to study the protein-protein interaction of Hub1/Snu66, which is linked to several human pathologies, such as hypercholesterolemia, premature aging, neurodegenerative diseases, and cancer. To identify small molecule ligands for Hub1, we used the interface analysis, peptide modeling of the Hub1/Snu66 interaction and the fragment-based NMR screening. Fragment-based NMR screening has not proven sufficient to unambiguously search for fragments that bind to the Hub1 protein. This was because the Snu66 binding pocket of Hub1 is occupied by pH-sensitive residues, making it difficult to distinguish between pH-induced NMR shifts and actual binding events. The NMR analyses were therefore verified experimentally by microscale thermophoresis and by NMR pH titration experiments. Our study found two small peptides that showed binding to Hub1. These peptides are the first small-molecule ligands reported to interact with the Hub1 protein.